261 filings
Page 9 of 14
8-K
447kqyv12kb
7 Dec 17
Sage Therapeutics Reports PositiveTop-line Results from Phase 2 Placebo-Controlled Trial ofSAGE-217 in Major Depressive Disorder
12:00am
8-K
q0p9p09cfj7ioo
17 Nov 17
Sage Therapeutics Announces Closing of $345 Million Public Offering of Common
12:00am
8-K
es8d2u
15 Nov 17
Sage Therapeutics Announces Proposed Public Offering of Common Stock
12:00am
424B5
w3p4 bhoksmj
15 Nov 17
Prospectus supplement for primary offering
12:00am
424B5
z5jm8rm byn69
13 Nov 17
Prospectus supplement for primary offering
12:00am
8-K
32ubzbbwsbs 41p
9 Nov 17
Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
12:00am
8-K
pbd8y2s sl
8 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
jfu7g51z64vj bwo
7 Nov 17
Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update
12:00am
8-K
m3d vu9i2dub3rqm2fni
12 Sep 17
Sage Therapeutics ReportsTop-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus
12:00am
8-K
5lri2h 58l
3 Aug 17
Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update
12:00am
CT ORDER
a42m4fxs h44lsa9nb6s
26 Jul 17
Confidential treatment order
12:00am
8-K
g4lpo990chtsf qdq
8 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
1evdaym jz
9 May 17
Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update
12:00am
DEFA14A
38ifnr
28 Apr 17
Additional proxy soliciting materials
12:00am
8-K
p3ypxlaur3l3zu
9 Mar 17
Departure of Directors or Certain Officers
12:00am